The comprehensive study of the global pharmacogenomics services market by Our Research Team extensively covers the following:

• Market numbers on micro segments influencing the market
• More than 200 products present in the market
• Over 20 brands were evaluated
• Market share analysis for more than 15 product categories
• End-user preference data for over 20 end users
• Detailed global and regional market share analysis, including the scrutiny of more than 16 countries
• Study of data of more than 19 companies

Besides these parameters, the study also encompasses the market growth drivers, opportunities, market restraining factors, competition mapping, segmental analysis, and a visual dashboard of 100+ products.

Our Research Team study indicates that the increasing prevalence of infectious diseases and various types of cancer, rising adoption of personalized medicine shifting the paradigm from reaction to prevention, increasing rate of adverse drug reaction, and surge in usage of pharmacogenomics for drug discovery and development, among others, are fueling the growth of the global pharmacogenomics services market.

The market intelligence report by Our Research Team also highlights opportunities existing in the market, such as massive scope for adoption of pharmacogenomics in emerging nations, technological advancements in molecular techniques for pharmacogenomic diagnostic tests, and rise of direct-to-consumer (DTC) testing services.

To gain a holistic view of the market, data from different market segments has been analyzed minutely. These segments include service, application, technology, end user, and region. The service and ecosystem analysis of the global market include data analysis on the satisfaction level of different pricing analyses of preferred pharmacogenomics services products and services. Pertaining to the market segmentation, the service segment is segmented into genotyping, single nucleotide polymorphism (SNP) identification, pharmacogenetic testing, and other services.

Additionally, the application segment of the market has been segmented into oncology, infectious disease, neurology/psychiatry, cardiovascular, and other applications.
Further, the technology segment has been broadly classified into polymerase chain reaction (PCR), microarray, sequencing, and other technologies. Finally, the end-user segment has been segmented into research organizations, pharmaceutical companies, diagnostic centers, and other end users.

Emphasizing the dominance of the North America region in the global pharmacogenomics services market in 2021 and 2031, Nitish Singh, Analyst – Our Research Team, states, ” In North America, several emerging and legacy companies are focusing on expanding their respective pharmacogenomics services portfolio for clinical and research use. Additionally, emerging companies are massively investing in developing advanced pharmacogenomic tests based on molecular assay technologies, particularly for clinical applications to enable precision medicine. Moreover, the significant uptake of research activities on drug and biomarker discovery, increase in prevalence of cancer, cardiovascular, and infectious disease, and rise in awareness among patients regarding targeted therapeutics, among others, promoted the adoption of pharmacogenomic tests by end users.”

Key insights are drawn from in-depth interviews with the key opinion leaders of more than 19 leading companies, market participants, and vendors. Key players profiled in the report include Laboratory Corporation of America Holdings, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., QIAGEN N.V., Illumina, Inc., Quest Diagnostics Incorporated, Abbott Laboratories, Mesa Laboratories, Inc., Admera Health, LLC, geneOmbio Technologies Pvt Ltd., Dynamic DNA Laboratories, Exact Sciences Corporation, Myriad Genetics, Inc., OMECare, Precipio, 23andMe, Inc., OneOme, LLC, OPKO Health, and DiaCarta, Inc.

The study also offers strategic recommendations to help organizations track various pharmacogenetic tests changing market dynamics. The recommendations by Our Research Team also offer bespoke research services to help organizations meet their objectives.

Who should buy this report?

• Pharmacogenomic test developers and providers that are involved in the development and commercialization of pharmacogenomics services.
• Emerging companies in the field of pharmacogenomics services to assess the market situation.

How can market intelligence on Pharmacogenomics services add value to an organization’s decision-making process?

• Aids in pharmacogenomic test development
• Helps in targeting a segment for launching new tests
• Offers go to market access strategies
• Supports in diversifying the portfolio basis risk and progression of underlying technologies
• Helps in analyzing specifications
• Aids in understanding the end-user landscape
• Helps in gaining holistic views pertaining to regions and understanding the market potential of the countries.
• Supports in analyzing the competitive landscape to gain an understanding of the business strategies incorporated by the companies

Insightful Questions Covered to Enable Companies to Take Strategic Decisions

• How are pharmacogenomics services revolutionizing clinical diagnostics and translational research?
• What are the major market drivers, challenges, and opportunities in the global pharmacogenomics services market?
• What are the underlying structures resulting in the emerging trends within the global pharmacogenomics services market?
• How did the COVID-19 pandemic impact the global pharmacogenomics services ecosystem?
• What are key development strategies that are being implemented by the major players in order to sustain themselves in the competitive market?
• What are the key regulatory implications in developed and developing regions pertaining to the use of pharmacogenomics services?
• What are the potential entry barriers expected to be faced by the companies willing to enter a particular region?
• How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each of the segments? Following are the segments:
o Service (genotyping, SNP identification, pharmacogenetic testing, and other services)
o Technology (polymerase chain reaction, microarray, sequencing, and other technologies)
o Application (oncology, infectious disease, neurology/psychiatry, cardiovascular, and other applications)
o End user (research organizations, pharmaceutical companies, diagnostic centers, and other end users)
o Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)
• What are the growth opportunities for the pharmacogenomics services companies in the region of their operation?
• Who are the leading players with significant offerings in the global pharmacogenomics services market?
• Which companies are anticipated to be highly disruptive in the future, and why?
Buy the report: Pharmacogenomics Services Market – A Global and Regional Analysis: Focus on Service, Technology, Application, End User, and Country-Wise Analysis – Analysis and Forecast, 2021-2031
[contact-form-7]

The post CRI Report: pharmacogenomics services market is projected to reach $9,346.8 million by 2031 first appeared on CRI Report.